Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Amortization of Deferred Charges (2020 - 2021)

Crescent Biopharma (CBIO) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $189440.0 as the latest value for Q3 2021.

  • On a quarterly basis, Amortization of Deferred Charges rose 10.08% to $189440.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $731302.0, a N/A change, with the full-year FY2020 number at $680845.0, up 9.8% from a year prior.
  • Amortization of Deferred Charges was $189440.0 for Q3 2021 at Crescent Biopharma, up from $184935.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $189440.0 in Q3 2021 to a low of $164262.0 in Q1 2020.